Puma Pumps up Biotech ETFs

Shares of Puma Biotechnology (NYSE: PBYI) are up more than 277% Wednesday on volume that is already better than 10 times the daily average after the company said its experimental breast cancer treatment, neratinib, proved successful in a Phase III trial. “The primary endpoint of the trial was...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.